Cervical malignancies typically spread via local cervical extension or pelvic lymphatic channels. However, unusual histological variants sometimes display unexpected metastatic patterns that challenge clinicians. Specifically, cervical villoglandular adenocarcinoma represents a rare cervical neoplasm recognized for an indolent clinical course. Despite this favorable reputation, clinicians must remain alert for deceptive distant adnexal spread.

Clinical Presentation of Cervical Villoglandular Adenocarcinoma

Cervical villoglandular adenocarcinoma predominantly affects young women of reproductive and perimenopausal age. Clinicians frequently encounter these tumors during routine evaluations for abnormal uterine bleeding or persistent postcoital spotting. On pelvic speculum examination, the tumor characteristically forms an exophytic, papillary, or friable cervical mass. Consequently, examining physicians may initially mistake the lesion for an endocervical polyp or benign condyloma. In addition, cervicovaginal cytology often fails to capture the true architectural complexity.

Histopathologically, the malignancy displays tall, slender villous projections lined by stratified columnar epithelium. The cellular components exhibit mild to moderate cytological atypia with infrequent mitotic figures. Because most cases demonstrate superficial stromal invasion, standard guidelines often endorse conservative surgical approaches. Therefore, gynecologic oncologists frequently consider fertility-sparing procedures for localized stage I disease. However, aggressive phenotypes occasionally emerge and exhibit atypical metastatic spread. Clinicians must thoroughly evaluate depth of invasion and lymphovascular space involvement. As a result, meticulous histopathological examination prevents underestimating tumor aggressiveness.

Ovarian Metastasis Mimicking Borderline Ovarian Neoplasms

Ovarian metastases originating from primary cervical cancer occur in fewer than two percent of patients. Furthermore, adnexal dissemination from well-differentiated villoglandular neoplasms remains exceptionally extraordinary. In this reported index case, the cervical tumor spread directly to the ovary with an alarming morphological disguise. The metastatic ovarian mass exhibited prominent papillary fronds and mild cytological atypia without obvious destructive stromal invasion.

Consequently, surgical pathologists faced a major diagnostic challenge during microscopic evaluation. The metastatic lesion closely mimicked a primary ovarian borderline seromucinous or mucinous tumor. Primary borderline ovarian neoplasms typically feature intricate papillary branching, nuclear pseudostratification, and an absence of overt destructive infiltration. In addition, clinicians encountering concurrent cervical and ovarian lesions often suspect independent synchronous primary malignancies. Misclassifying an ovarian metastasis as an independent primary borderline tumor carries severe therapeutic consequences. Specifically, such diagnostic errors lead to inaccurate surgical staging, inappropriate observation, and omission of essential adjuvant systemic therapies. Thus, pathologists must maintain heightened suspicion whenever complex adnexal papillary architecture accompanies cervical adenocarcinoma.

Immunohistochemical Profiling in Differential Diagnosis

Pathologists utilize targeted immunohistochemical panels to distinguish primary ovarian epithelial neoplasms from metastatic cervical adenocarcinomas. Primary ovarian borderline seromucinous tumors regularly demonstrate robust nuclear expression of estrogen receptor and progesterone receptor. In contrast, human papillomavirus-associated cervical adenocarcinomas consistently lack diffuse hormone receptor immunoreactivity. Moreover, primary ovarian tumors typically express Pax-8 and show patchy or negative p16 staining patterns.

Conversely, cervical villoglandular adenocarcinomas exhibit diffuse, strong, block-like immunoreactivity for p16INK4a in both nuclear and cytoplasmic compartments. This intense staining pattern signals functional retinoblastoma protein inactivation by viral E7 oncoproteins. In this index case, matching immunohistochemical expression profiles across both anatomical sites provided vital diagnostic evidence. Specifically, both the cervical lesion and the ovarian mass exhibited continuous p16 positivity alongside identical cytokeratin profiles. Furthermore, negative immunoreactivity for ovarian-specific lineage markers ruled out an independent primary adnexal origin. Consequently, immunohistochemistry confirmed that the ovarian lesion represented true metastatic spread rather than a second primary tumor. Thus, an objective antibody panel serves as an indispensable diagnostic safeguard in gynecologic pathology.

Molecular Validation Through HPV16 DNA Testing

While immunohistochemical staining offers substantial diagnostic clarity, molecular assays provide unequivocal confirmation in controversial presentations. High-risk human papillomavirus drives the oncogenesis of almost all cervical villoglandular carcinomas. Specifically, genotype HPV16 and genotype HPV18 represent the most prevalent oncogenic drivers detected in clinical cohorts. In contrast, genuine primary epithelial and borderline ovarian tumors do not harbor high-risk papillomavirus genomes.

Therefore, performing molecular HPV DNA detection directly on formalin-fixed paraffin-embedded tissue blocks provides decisive discriminatory value. In this reported patient, clinicians performed polymerase chain reaction assays and in situ hybridization on both cervical and ovarian specimens. The molecular testing identified identical HPV16 DNA sequences within both tumor sites. This definitive genetic match conclusively proved clonal identity between the primary cervical tumor and the ovarian mass. Furthermore, detecting identical viral DNA eliminated the diagnostic hypothesis of synchronous independent primary tumors. As a result, molecular genotyping provided unassailable proof of metastatic dissemination. Today, molecular diagnostics bridge critical knowledge gaps whenever deceptive morphological mimics obscure clinical evaluation in pelvic oncology.

Multimodal Management and Therapeutic Implications

Accurate identification of ovarian metastasis dramatically changes the clinical stage and therapeutic roadmap for patients with cervical cancer. Localized cervical villoglandular adenocarcinoma usually permits fertility-sparing surgery or radical hysterectomy alone. However, adnexal involvement automatically upstages the condition to advanced stage IVB disease under FIGO criteria. Consequently, surgical and medical oncologists must immediately adopt an aggressive multimodality approach.

In this index case, surgeons performed complete cytoreductive surgery, including radical hysterectomy, bilateral salpingo-oophorectomy, and systematic pelvic lymphadenectomy. Following recovery from surgery, the patient received adjuvant concurrent platinum-based chemoradiotherapy. This comprehensive adjuvant treatment targeted potential microscopic residual disease within the pelvis and retroperitoneal lymphatic beds. Remarkably, the patient responded exceptionally well and remained completely recurrence-free during clinical surveillance. This favorable outcome confirms that aggressive multimodal therapy can achieve sustained disease remission even in advanced presentations. Moreover, prompt recognition of ovarian metastasis prevented undertreatment with incomplete surgical resection. Therefore, cohesive multidisciplinary collaboration among gynecologists, oncologists, and pathologists remains paramount for optimizing long-term survival in rare gynecologic malignancies.

Frequently Asked Questions

Why does cervical villoglandular adenocarcinoma rarely metastasize to the ovaries?

Cervical villoglandular adenocarcinoma typically features well-differentiated cytology, minimal cellular atypia, and superficial stromal invasion. Most patients present with localized stage I disease and rarely exhibit lymphovascular space invasion. Consequently, distant hematogenous or trans-coelomic dissemination to the adnexa remains exceptionally unusual. However, aggressive biological subclones can occasionally breach vascular barriers. Therefore, clinicians must thoroughly investigate any synchronous ovarian mass to avoid missing unexpected metastatic deposits.

How does immunohistochemistry distinguish cervical metastasis from a primary ovarian tumor?

Pathologists evaluate distinct immunohistochemical expression profiles to resolve this diagnostic dilemma. HPV-associated cervical villoglandular adenocarcinoma exhibits diffuse, block-positive p16 immunoreactivity and lacks estrogen and progesterone receptors. Conversely, primary ovarian seromucinous and endometrioid tumors typically display strong hormone receptor positivity and patchy p16 staining. Furthermore, ovarian tumors frequently express PAX-8. Therefore, combining p16, hormone receptors, and organ-specific markers reliably separates deceptive cervical metastases from true primary ovarian borderline tumors.

What treatment protocol is recommended when cervical adenocarcinoma metastasizes to the ovary?

When cervical adenocarcinoma spreads to the ovary, the disease stage advances to stage IVB under FIGO staging criteria. Consequently, treatment shifts from localized surgery to comprehensive multimodal therapy. Surgeons perform complete cytoreductive surgery, including radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy. Subsequently, patients receive adjuvant concurrent platinum-based chemoradiotherapy to control microscopic pelvic and systemic residual disease. This aggressive multimodality approach significantly minimizes recurrence risk and prolongs disease-free patient survival.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Ma N et al. Villoglandular Adenocarcinoma of the Cervix With Ovarian Metastasis Mimicking a Borderline Ovarian Tumor: A Rare Case Report. Clin Case Rep. 2026 Nov undefined. doi: 10.1002/ccr3.73677. PMID: 42926921.
2. Dietl AK, Beckmann MW, Aumann K. Villoglandular adenocarcinoma of the uterine cervix: a systematic review and meta-analysis. Arch Gynecol Obstet. 2021;304(2):317-327.
3. Stolnicu S, Barsan I, Hoang L, et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC). Am J Surg Pathol. 2018;42(2):214-226.